亚辉龙公告，公司控股股东、实际控制人兼董事长胡鹍辉持有2.22亿股，占38.9466%，拟自2025年9月 10日至2025年12月9日通过集中竞价不超过570.43万股、大宗交易不超过1140.85万股，合计减持不超 1711.28万股，即不超3%；副总经理兼核心技术人员肖育劲持有248万股，占0.4348%，同期拟减持不超 62万股，占0.1087%。 ...

Company Overview - Shenzhen Aihuilong Biotechnology Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic instruments and related reagents, primarily using chemiluminescence immunoassay technology [2] - The company has developed a fully automated immunoassay system, breaking the technological monopoly of foreign giants in the field of acridine ester chemiluminescence [2] - Aihuilong's quality management system meets international standards, with major products certified by ISO9001, ISO13485, and EU CE [2] Financial Performance - For Q1 2025, the company reported revenue of 418 million yuan, a year-on-year decrease of 3.13%, and a net profit of 10.148 million yuan, down 84.63% year-on-year [2] - The sales gross margin stood at 59.49% [2] Market Position - As of August 15, Aihuilong's stock closed at 15.51 yuan, with a rolling PE ratio of 36.02, and a total market capitalization of 8.847 billion yuan [1] - The average PE ratio in the medical device industry is 56.58, with a median of 39.97, placing Aihuilong at the 70th position in the industry ranking [1][3] - The company has one institutional holder, with a total holding of 0.14 thousand shares, valued at 0.00 billion yuan [1]

资金流向方面，今日主力资金净流出1229.49万元，占比成交额13.14%。其中，超大单净流出471.25万 元、占成交额5.04%，大单净流出758.23万元、占成交额8.1%，中单净流出流出386.40万元、占成交额 4.13%，小单净流入1615.89万元、占成交额17.27%。 来源：金融界 亚辉龙最新一期业绩显示，截至2025一季报，公司营业总收入4.18亿元、同比减少3.13%，归属净利润 1014.80万元，同比减少84.63%，扣非净利润3690.52万元，同比减少35.44%，流动比率2.124、速动比率 1.432、资产负债率37.24%。 天眼查商业履历信息显示，深圳市亚辉龙生物科技股份有限公司，成立于2008年，位于深圳市，是一家 以从事专用设备制造业为主的企业。企业注册资本57042.68万人民币，实缴资本57026.74万人民币。公 司法定代表人为宋永波。 金融界消息 截至2025年8月15日收盘，亚辉龙（688575）报收于15.51元，上涨1.44%，换手率1.06%， 成交量6.05万手，成交金额9357.45万元。 通过天眼查大数据分析，深圳市亚辉龙生物科技股份有限公司共对 ...

Core Viewpoint - The company, 亚辉龙, is experiencing a decline in stock price and profitability, with a significant drop in net profit and revenue in the latest quarterly report, while its valuation metrics indicate it is underperforming compared to industry averages. Company Overview - 亚辉龙 specializes in the research, production, and sales of in vitro diagnostic instruments and related reagents, primarily using chemiluminescence immunoassay technology [2] - The company has developed a fully automated immunoassay system, breaking the technological monopoly of foreign giants in the field of acridine ester direct chemiluminescence [2] - The quality management system of the company meets international standards, with major products certified by ISO9001, ISO13485, and EU CE [2] Financial Performance - For Q1 2025, the company reported revenue of 418 million yuan, a year-on-year decrease of 3.13%, and a net profit of 10.148 million yuan, down 84.63% year-on-year, with a gross margin of 59.49% [2] - The current stock price is 15.29 yuan, down 2.61%, with a rolling PE ratio of 35.51 times and a total market capitalization of 8.722 billion yuan [1] Industry Comparison - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, placing 亚辉龙 at the 70th position in the industry ranking [1][3] - The company’s PE ratio is significantly lower than the industry average, indicating potential undervaluation relative to peers [3]

与射血分数降低型心力衰竭(HFrEF)不同，HFpEF患者因心肌结构与功能改变更隐蔽，传统诊断手段长 期面临"瓶颈"——超声心动图操作依赖经验、生物标志物(如BNP/NT-proBNP)特异性不足，导致临床漏 诊率高达30%以上，多数患者确诊时已进入中晚期，治疗难度与医疗成本显著上升。 HFpEF诊断试剂不仅填补了全球HFpEF特异性体外诊断领域的技术空白，重塑心衰疾病筛查、诊断乃至 慢病管理的现有模式，更凭借其临床价值与商业潜力，为体外诊断赛道注入新的增长预期。 亚辉龙此次发布的联合创新成果——射血分数保留型心力衰竭(HFpEF)诊断试剂，让亚辉龙在心血管疾 病领域更进一步，在代谢组学检测领域取得关键突破，使心肌标志物检测矩阵从传统的心肌损伤(hs- cTnI)、心功能评估(BNP/NT-proBNP)扩展到能量代谢监测维度。 近日，"高性能免疫现场快速检测系统研发项目会议暨BCAA、BCKA创新成果发布"在南京隆重举行。 会议上，亚辉龙(688575.SH)与新加坡国立大学心血管中心的王义斌教授联合宣布，全球首个基于支链 氨基酸/支链α酮酸(BCAA/BCKA)比值检测的射血分数保留型心力衰竭(HFpEF ...

亚辉龙此次发布的联合创新成果射血分数保留型心力衰竭（HFpEF）诊断试剂，让亚辉龙在心血管疾病 领域更进一步，在代谢组学检测领域取得关键突破，心肌标志物检测矩阵从传统的心肌损伤（hs- cTnI）、心功能评估（BNP/NT-proBNP）扩展到能量代谢监测维度。 值得注意的是，亚辉龙在IVD（体外诊断）行业精耕细作十七年，高度重视心血管疾病领域布局，公司 构建了多个核心技术平台。其中微流控化学发光技术作为"十四五"国家重点研发计划的核心攻关方向， 可实现15分钟内完成多个心血管项目的全血联检，为胸痛中心等急救场景提供黄金时间窗口。 BCAA/BCKA生化检测体系的加入，使生化检测平台与现有免疫检测平台形成互补，配合超声等影像学 检查，最终构建起"影像结构评估+生物标志物功能检测+代谢动态监测"的三维诊疗体系。 业内人士表示："心衰作为心血管疾病的终末战场，治疗缺口巨大。当前国内药物市场规模仅约100亿 元，但创新药械正以超50%的增速打开空间。"HFpEF诊断试剂不仅填补了全球HFpEF特异性体外诊断 领域的技术空白，重塑心衰疾病筛查、诊断乃至慢病管理的现有模式，更凭借其临床价值与商业潜力， 为体外诊断赛道注 ...

值得注意的是，亚辉龙在IVD（体外诊断）行业深耕细作十七年，高度重视心血管疾病领域布局，公司 构建了多个核心技术平台。其中微流控化学发光技术作为"十四五"国家重点研发计划的核心攻关方向， 可实现15分钟内完成多个心血管项目的全血联检，为胸痛中心等急救场景提供黄金时间窗口。 BCAA/BCKA生化检测体系的加入，使生化检测平台与现有免疫检测平台形成互补，配合超声等影像学 检查，最终构建起"影像结构评估+生物标志物功能检测+代谢动态监测"的三维诊疗体系。 （文章来源：证券时报网） 与射血分数降低型心力衰竭（HFrEF）不同，HFpEF患者因心肌结构与功能改变更隐蔽，传统诊断手段 长期面临"瓶颈"——超声心动图操作依赖经验、生物标志物（如BNP/NT-proBNP）特异性不足，导致临 床漏诊率高达30%—70%，多数患者确诊时已进入中晚期，治疗难度与医疗成本显著上升。 近日，"高性能免疫现场快速检测系统研发项目会议暨BCAA、BCKA创新成果发布"在南京隆重举行。 会议上，亚辉龙（688575.SH）与新加坡国立大学心血管中心的王义斌教授联合宣布，全球首个基于支 链氨基酸/支链α酮酸（BCAA/BCKA）检测的射血 ...

Core Insights - The annual meeting of Aihua Long Group focused on collaboration and innovation in the IVD industry, emphasizing the theme "Gathering Strength, Energy, and Climbing Peaks" [1] - The company highlighted significant achievements in 2024, including the full operation of its Shenzhen headquarters and the completion of the Hunan Xiangtan medical device industrial park, indicating an upgrade in capacity and layout [3] - Aihua Long aims to deepen partnerships and maintain academic leadership to navigate the challenges posed by industry adjustments and cost control policies [3][9] Company Developments - Aihua Long's core products, particularly the iFlash 3000 series, showed strong performance, contributing to the company's growth [3] - The company recognized outstanding partners during the meeting, aiming to inspire innovation and collaboration through awards [7] - The CEO, Hu Kunhui, expressed a commitment to continue the "Gathering Strength, Energy" philosophy and to strive for higher achievements alongside partners [9] Industry Trends - The IVD sector is currently facing pressures from DRG/DIP cost control policies and the implementation of mutual recognition of test results, leading to a decline in testing volumes [3] - Representatives from various partner organizations shared strategies for product upgrades and collaborative efforts to address industry challenges [5]

Group 1 - The company's stock price on August 7 was 15.81 yuan, down 0.94% from the previous trading day, with a trading volume of 92,949 lots and a transaction amount of 148 million yuan [1] - The company specializes in the research, production, and sales of in vitro diagnostic products, covering areas such as autoimmune, infectious immunity, reproductive health, and diabetes monitoring, with operations in over 120 countries and regions globally [1] - Recent data indicates that the revenue from the European region accounts for less than 10% of the company's total overseas revenue, with the company stating its overseas business spans the Americas, Europe, Asia, and Africa [1] Group 2 - On the same day, the net outflow of main funds was 6.023 million yuan, with a cumulative net outflow of 8.0801 million yuan over the past five days [2]

Company Overview - Shenzhen Aihuilong Biotechnology Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic instruments and related reagents, primarily using chemiluminescence immunoassay technology [2] - The company has developed a fully automated immunoassay system, breaking the technological monopoly of foreign giants in the field of acridinium ester direct chemiluminescence [2] - Aihuilong's quality management system meets international standards, with major products certified by ISO9001, ISO13485, and EU CE [2] Financial Performance - For Q1 2025, the company reported revenue of 418 million yuan, a year-on-year decrease of 3.13%, and a net profit of 10.148 million yuan, down 84.63% year-on-year, with a gross margin of 59.49% [2] - As of August 6, the company's stock closed at 15.96 yuan, down 1.30%, with a rolling PE ratio of 37.06 and a total market capitalization of 9.104 billion yuan [1] Industry Comparison - The average PE ratio for the medical device industry is 53.93, with a median of 37.81, placing Aihuilong at the 74th position within the industry [1][3] - The company's PE ratio is significantly lower than the industry average, indicating potential undervaluation compared to peers [3]